Skip to content
Dr. Grey AI

Peptide

Lanreotide (Somatuline)

Lanreotide is a long-acting synthetic octapeptide analog of somatostatin, FDA-approved for treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The landmark CLARINET trial demonstrated 53% reduction in disease progression risk in metastatic GEP-NETs. Available as an extended-release depot formulation (Somatuline Depot) for once-monthly injection.

Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.

Best evidence
Grade A
Conditions studied
2
Outcomes
14
Graded outcomes
7421

Evidence by condition

  • Strong
  • Moderate
  • Limited
  • Very limited

2 conditions, plus general outcomes

Acromegaly

Acromegaly: outcomes studied for Lanreotide (Somatuline)
GradeOutcomeEffectSizeStudiesPeopleStudies list
Acromegaly Symptoms

Significant improvement in soft tissue swelling, headaches, joint pain, and fatigue associated with acromegaly.

Improves (the measure goes down)Moderate effect27 studies

Studies that measured acromegaly symptoms

and 17 more in the citations list

GH Suppression (Acromegaly)

50-60% of patients achieve GH control (<2.5 ng/mL) with long-term lanreotide treatment. FDA-approved for acromegaly.

Improves (the measure goes down)Large effect26 studies

Studies that measured gh suppression (acromegaly)

and 16 more in the citations list

IGF-1 Normalization

Approximately 50% of acromegaly patients achieve IGF-1 normalization with lanreotide depot treatment.

Changes; see studiesLarge effect18 studies

Studies that measured igf-1 normalization

and 8 more in the citations list

Neuroendocrine Tumors

Neuroendocrine Tumors: outcomes studied for Lanreotide (Somatuline)
GradeOutcomeEffectSizeStudiesPeopleStudies list
Tumor Stabilization (NETs)

Stable disease rates of 15-89% in clinical trials. Phase II studies show significant antitumor effects with disease control in majority of patients.

Improves (the measure goes up)Large effect25 studies

Studies that measured tumor stabilization (nets)

and 15 more in the citations list

Progression-Free Survival (NETs)

CLARINET trial: 53% reduction in disease progression risk (HR 0.47, P<0.001). 65.1% vs 33.0% PFS at 24 months. Median PFS not reached vs 18 months placebo.

Improves (the measure goes up)Large effect24 studies

Studies that measured progression-free survival (nets)

and 14 more in the citations list

Carcinoid Syndrome Symptoms

FDA-approved for symptomatic control of flushing and diarrhea associated with carcinoid syndrome. Significant QOL improvement in symptomatic patients.

Improves (the measure goes down)Large effect22 studies

Studies that measured carcinoid syndrome symptoms

and 12 more in the citations list

VIPoma Symptoms

Effective for controlling watery diarrhea and electrolyte disturbances in VIP-secreting tumors.

Improves (the measure goes down)Large effect22 studies

Studies that measured vipoma symptoms

and 12 more in the citations list

General

General: outcomes studied for Lanreotide (Somatuline)
GradeOutcomeEffectSizeStudiesPeopleStudies list
Anti-Cancer Activity

33 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.

Improves (the measure goes up)Moderate effect11 studies

Studies that measured anti-cancer activity

and 1 more in the citations list

Safety/Tolerability

9 human trials support this finding. Human clinical trial data available.

Improves (the measure goes up)Moderate effect9 studies

Studies that measured safety/tolerability

Pulmonary Function

5 human trials support this finding. Human clinical trial data available.

Improves (the measure goes up)Small effect5 studies

Studies that measured pulmonary function

Liver Protection

5 human trials support this finding. Human clinical trial data available.

Improves (the measure goes up)Small effect5 studies

Studies that measured liver protection

Blood Glucose Control

3 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.

Improves (the measure goes down)Small effect5 studies

Studies that measured blood glucose control

GI Protection

4 human trials support this finding. Human clinical trial data available.

Improves (the measure goes up)Small effect4 studies
Kidney Function

2 human trials support this finding. Human clinical trial data available.

Improves (the measure goes up)Small effect2 studies

Key findings

  • Acromegaly SymptomsAcromegalyImproves (the measure goes down)
  • GH Suppression (Acromegaly)AcromegalyImproves (the measure goes down)
  • Tumor Stabilization (NETs)Neuroendocrine TumorsImproves (the measure goes up)

Safety notes in the studies

  • CLARINET trial: 53% reduction in disease progression risk (HR 0.47, P<0.001).

Studies cited

50 studies from PubMed

  1. Lanreotide protects against LPS-induced inflammation in endothelial cells and mouse lungs.Tissue barriers, 2025 · PMID 40241488
  2. Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases.Scientific reports, 2025 · PMID 40437077
  3. Safety profile of lanreotide: a retrospective post-marketing pharmacovigilance study based on the real-world data from FAERS database.Endocrine, 2025 · PMID 40468101
  4. Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.The oncologist, 2024 · PMID 38206830
  5. An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors.Expert opinion on drug safety, 2024 · PMID 38847075
  6. Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2.Journal of hematology & oncology, 2023 · PMID 38098114
  7. Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study.Neuroendocrinology, 2023 · PMID 36044870
  8. The Use of Lanreotide in the Treatment of Congenital Hyperinsulinism.The Journal of clinical endocrinology and metabolism, 2022 · PMID 35587448
  9. Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly.Expert review of clinical pharmacology, 2021 · PMID 34664531
  10. Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).BMC endocrine disorders, 2020 · PMID 32366244
  11. Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial.Lung cancer (Amsterdam, Netherlands), 2019 · PMID 31319970
  12. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.Gastroenterology, 2019 · PMID 31022403
  13. Further Evidence That Lanreotide Reduces Liver Growth in Patients With Polycystic Liver Disease, But Not the End of the Story.Gastroenterology, 2019 · PMID 31260661
  14. Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis.Investigational new drugs, 2019 · PMID 30536151
  15. The safety of lanreotide for neuroendocrine tumor.Expert opinion on drug safety, 2019 · PMID 30582380
  16. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trialsPituitary, 2018 · PMID 29357081
  17. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2018 · PMID 29547049
  18. Cost-effectiveness of acromegaly treatments: a systematic review.Pituitary, 2018 · PMID 30159696
  19. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.The oncologist, 2017 · PMID 28220021
  20. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.Expert opinion on pharmacotherapy, 2016 · PMID 26635177
  21. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.Current oncology reports, 2016 · PMID 26743514
  22. Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity With Lanreotide Autogel/Depot (LAN) Versus Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data.Clinical advances in hematology & oncology : H&O, 2016 · PMID 27168103
  23. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.Endocrine-related cancer, 2016 · PMID 26743120
  24. Lanreotide-conjugated PEG-DSPE micelles: an efficient nanocarrier targeting to somatostatin receptor positive tumors.Journal of drug targeting, 2015 · PMID 25366085
  25. Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015 · PMID 26073493
  26. Lanreotide and its Potential Applications in Polycystic Kidney and Liver Diseases.Current topics in medicinal chemistry, 2015 · PMID 26126910
  27. Pasireotide in Acromegaly: A Review.Drugs, 2015 · PMID 26017304
  28. Lanreotide in metastatic enteropancreatic neuroendocrine tumorsN Engl J Med, 2014 · PMID 25014687
  29. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trialJ Clin Endocrinol Metab, 2014 · PMID 24423301
  30. Lanreotide autogel(®): a review of its use in the treatment of patients with acromegaly.Drugs, 2014 · PMID 25193626
  31. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.The lancet. Diabetes & endocrinology, 2014 · PMID 25260838
  32. Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients.Lung cancer (Amsterdam, Netherlands), 2012 · PMID 22018594
  33. Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel).The Journal of clinical endocrinology and metabolism, 2011 · PMID 21697252
  34. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extensionPituitary, 2010 · PMID 19639415
  35. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.Pituitary, 2010 · PMID 19189218
  36. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegalyJ Endocrinol Invest, 2009 · PMID 19542735
  37. Efficacy of long-term lanreotide treatment in patients with acromegalyJ Clin Endocrinol Metab, 2009 · PMID 19266287
  38. Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC).Expert opinion on pharmacotherapy, 2009 · PMID 19191684
  39. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.Gastroenterology, 2009 · PMID 19646443
  40. Lanreotide Autogel: a review of its use in the management of acromegaly.Drugs, 2008 · PMID 18370450
  41. Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review.Neuro endocrinology letters, 2007 · PMID 18063933
  42. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegalyClin Endocrinol (Oxf), 2006 · PMID 16430722
  43. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center studyJ Endocrinol Invest, 2002 · PMID 12553557
  44. GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotideJ Endocrinol Invest, 2001 · PMID 11383906
  45. Established clinical use of octreotide and lanreotide in oncology.Chemotherapy, 2001 · PMID 11275701
  46. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patientsJ Clin Endocrinol Metab, 2000 · PMID 11078980
  47. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumorsActa Oncol, 1999 · PMID 11095353
  48. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptomsJ Clin Oncol, 1999 · PMID 10561168
  49. Phase I study of the somatostatin analogue somatuline in refractory small-cell lung carcinoma.Annals of oncology : official journal of the European Society for Medical Oncology, 1994 · PMID 8186178
  50. Somatuline and tamoxifen in postmenopausal breast cancer patients.Annals of the New York Academy of Sciences, 1993 · PMID 8279776